UK Patient-Derived Xenograft Model Market Research Report By Tumor Type (Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, Other Cancer), By Model Type (Mice, Rats) andBy End-User (Pharmaceutical, Biopharmaceutical Companies, Academic & Research Institutes, CROs, CDMOs)- Forecast to 2035

UK Patient-Derived Xenograft Model Market Overview

As per MRFR analysis, the UK Patient-Derived Xenograft Model Market Size was estimated at 14.12 (USD Million) in 2024.The UK Patient-Derived Xenograft Model Market Industry is expected to grow from 16(USD Million) in 2025 to 80 (USD Million) by 2035.

The UK Patient-Derived Xenograft Model Market CAGR (growth rate) is expected to be around 15.756% during the forecast period (2025 - 2035).

Key UK Patient-Derived Xenograft Model Market Trends Highlighted

The UK Patient-Derived Xenograft Model Market is witnessing significant market trends driven by the growing emphasis on personalized medicine and the need for more accurate cancer research models. With the NHS's increasing focus on advanced therapies and precision medicine, there is a heightened demand for innovative research models that can improve drug efficacy and reduce clinical trial failures.

This shift towards personalized therapies in the UK has made patient-derived xenograft models a vital tool for researchers and pharmaceutical companies, creating a favorable environment for market growth. Opportunities to be explored in this market include collaborations between academic institutions and biotech companies.The UK is home to top research universities and institutes, contributing to groundbreaking advancements in cancer treatment.

Initiatives such as the UK's Life Science Strategy support these collaborations, allowing researchers to leverage patient-derived xenograft models to explore new therapeutic options more effectively. The increasing investment in R&D, particularly in the field of oncology, further paves the way for innovations in model development. Recent trends indicate a shift towards the integration of advanced technologies, such as gene editing and biomanufacturing, into patient-derived xenograft models.

The use of these cutting-edge techniques in the UK enhances the relevance and applicability of these models in personalized treatment plans.Additionally, there is a growing interest in the development of organoid cultures and fully humanized models, expanding the capabilities of patient-derived xenografts. As regulatory environments become more supportive of these innovations, the UK market stands to benefit from expanded research applications and improved patient outcomes, solidifying its position as a leader in cancer research and therapeutics.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

UK Patient-Derived Xenograft Model Market Drivers

Rising Cancer Incidence in the UK

The growing prevalence of cancer in the United Kingdom significantly drives the UK Patient-Derived Xenograft Model Market. According to statistics from the UK government, cancer diagnoses have increased by nearly 7% from 2015 to 2020, with over 377,000 new cases reported annually. The National Health Service's (NHS) focus on innovative cancer treatment solutions fuels the demand for advanced models in researching cancer therapies.

Organizations such as Cancer Research UK actively advocate for funding in Research and Development (R&D) to create better treatment methodologies using patient-derived xenograft models. This change in medicine takes into account sociodemographic patient characteristics on an individual level and tumor biology, and therefore contributes to significant market growth in the coming years.

Support from Government and Research Institutions

The UK government and prominent research institutions are increasingly supporting initiatives that foster innovation in life sciences and oncology research. The UK government has invested substantially in biomedical research, amounting to billions over the past decade. Research initiatives led by institutions such as the Francis Crick Institute and University College London focus on developing patient-derived models to enhance drug testing and therapeutic research.

Such government backing is accelerating the development and adoption of patient-derived xenograft models, positioning them as vital tools in combating cancer and enhancing patient outcomes.

Technological Advancements in Model Development

Advancements in biotechnological practices present a significant driver for the UK Patient-Derived Xenograft Model Market. Continuous innovation in tissue engineering, gene editing, and biomarker identification is enabling the creation of more accurate patient-derived models. Reports suggest that the implementation of CRISPR technologies has grown in research labs, enhancing model specificity and efficacy.

Collaborations between top biotechnology firms, such as of Horizon Discovery and AstraZeneca, further fuel innovation, making it crucial for hospitals and research facilities to adopt these advanced paradigms in their oncology research.

Increasing Investment in Personalized Medicine

The growing trend towards personalized medicine has a profound impact on the UK Patient-Derived Xenograft Model Market. The UK government and various health organizations are investing heavily in tailoring treatments to fit individual patient profiles. Reports indicate that the personalized medicine market in the UK is expected to reach significant benchmarks, with an estimated growth rate around 10% annually.

The push for customized therapies necessitates tools such as patient-derived xenograft models to ascertain effective treatment protocols, driving demand within the market substantially.

UK Patient-Derived Xenograft Model Market Segment Insights

Patient-Derived Xenograft Model Market Tumor Type Insights

The UK Patient-Derived Xenograft Model Market is witnessing a significant evolution, particularly within the Tumor Type segment, which is gaining pivotal relevance in the realm of oncology research and therapeutic development. As cancer continues to be a leading cause of mortality in the UK, the necessity for precise research models has never been more critical. Tumor Type classifications, including Lung Cancer, Pancreatic Cancer, Prostate Cancer, Breast Cancer, and other variants, play an essential role in tailoring treatments and understanding tumor biology.

Lung Cancer, noted for its high incidence rates in the UK, dominates the market owing to the pressing need for innovative therapies and research methodologies. This has steered Research and Development efforts toward specialized xenograft models that accurately mimic patient-specific tumors, facilitating personalized medicine approaches. Pancreatic Cancer represents another area of significant research focus due to its aggressive nature and often late-stage diagnosis.

The demand for Patient-Derived Xenograft Models in this field is increasing as scientists strive to uncover novel treatment pathways. Prostate Cancer, prevalent among men in the UK, fuels a growing need for experimental models that can replicate the complexity of oncogenic processes and therapeutic resistance, which supports advancements in precision oncology. On the other hand, Breast Cancer, noted for its diverse subtype variability, continues to evolve as a focal point for researchers, leveraging xenograft models to explore targeted therapies and understand metastatic behavior.

Other Cancer types also contribute to the UK Patient-Derived Xenograft Model Market with specific focus areas emerging, as researchers aim to replicate and study various less common malignancies effectively. Understanding the dynamics within the Tumor Type segment is crucial for grasping the overall landscape of the UK Patient-Derived Xenograft Model Market. The advancements in genomic technologies and the push towards personalized approaches further enhance the relevance of these segments, driving market growth as researchers and healthcare providers collaborate to combat the challenges posed by an array of cancers.

Source: Primary Research, Secondary Research, MRFR Database and Analyst Review

Patient-Derived Xenograft Model Market Model Type Insights

The UK Patient-Derived Xenograft Model Market is experiencing notable growth, particularly in its Model Type segmentation which includes Mice and Rats. The demand for Mice in xenograft models is prominent due to their biological and genetic similarities to humans, making them invaluable for research in understanding tumor biology and drug efficacy. Rats also serve an essential role, offering advantages in pharmacokinetics and toxicology studies, contributing significantly to Research and Development efforts in the biopharmaceutical sector.

Continued advancements in genetic engineering and the development of more sophisticated models enhance the capabilities of these organisms, aligning with the UK's focus on innovative medical research.Furthermore, the increasing prevalence of cancers and the need for personalized medicine are driving growth in the Patient-Derived Xenograft Model Market. While both Mice and models are critical for preclinical validation, the ongoing enhancement of research methodologies is creating opportunities for expanded applications and improved therapeutic strategies in the UK healthcare industry.

Patient-Derived Xenograft Model Market End-User Insights

The UK Patient-Derived Xenograft Model Market is experiencing notable developments across its End-User segment, which encompasses a diverse range of entities including Pharmaceutical companies, Biopharmaceutical companies, Academic and Research Institutes, Contract Research Organizations (CROs), and Contract Development and Manufacturing Organizations (CDMOs). Pharmaceutical and Biopharmaceutical companies leverage patient-derived xenograft models extensively for drug discovery and preclinical testing, enabling the accelerating of drug development processes.

Academic and Research Institutes are pivotal in pushing the boundaries of cancer research, as they utilize these models to understand disease mechanisms and evaluate treatment efficacy. Additionally, CROs play a significant role by providing essential outsourced research services that enhance efficiency in clinical trials, while CDMOs help streamline the development and manufacturing processes tailored to specific therapeutic needs. The increasing focus on personalized medicine and the rising investment in innovative cancer therapies are expected to drive substantial growth in these segments.

This upward trend emphasizes the significance of patient-derived xenograft models, bringing opportunities for researchers to explore novel therapeutic avenues tailored to the unique genomic profiles of patients in the UK.

UK Patient-Derived Xenograft Model Market Key Players and Competitive Insights

The UK Patient-Derived Xenograft Model Market has seen significant advancements in recent years, reflecting the growing demand for effective preclinical models that accurately represent human tumors. These models play a crucial role in cancer research and drug development, enabling researchers to test therapeutic responses in conditions that closely mimic the human physiological environment. The competitive landscape is characterized by a mix of established players and emerging companies, all vying for a share of the market while addressing the challenges posed by complex tumor biology and the need for more personalized treatments.

Robust R&D efforts, strategic collaborations, and the integration of cutting-edge technologies are key drivers for companies seeking to enhance their product offerings and improve market positioning.Asterand Bioscience possesses a strong presence in the UK Patient-Derived Xenograft Model Market, leveraging its extensive expertise in sourcing, characterizing, and developing patient-derived tissues and models. The company is recognized for its commitment to advancing personalized medicine, with a focus on delivering high-quality PDX models that are tailored to specific patient profiles.

This enables pharmaceutical and biotechnological organizations to gain meaningful insights into therapeutic efficacy and safety. Asterand Bioscience benefits from its substantial biorepository and a wealth of clinical data, which enhance its ability to provide innovative solutions and cater to the unique needs of UK-based researchers and drug developers.Horizon Discovery is another significant player in the UK Patient-Derived Xenograft Model Market, known for its pioneering efforts in gene editing and custom model development.

The company offers a variety of key products and services, including patient-derived xenografts engineered to express specific genetic alterations, providing vital insights into cancer biology and therapy response. Horizon Discovery’s market presence is strengthened by its focus on innovative scientific solutions and its collaborations with academic institutions and industry partners to push the boundaries of cancer research. The company has continuously invested in expanding its product portfolio and enhancing its capabilities, evidenced by strategic acquisitions that bolster its position within the market.

With a reputation for excellence in preclinical oncology, Horizon Discovery remains dedicated to supporting the UK's evolving landscape in patient-derived models, catering to the diverse and specialized needs within the healthcare sector.

Key Companies in the UK Patient-Derived Xenograft Model Market Include

• Asterand Bioscience


• Horizon Discovery


• Medimmune


• NantCell


• Ascendance Biomedical


• Crown Bioscience


• Tissue Solutions


• Thermo Fisher Scientific


• OncoOne


• Charles River Laboratories


• Xenograft Technologies


• Genomatix


• Irvine Scientific


• The Jackson Laboratory


• James Harper

UK Patient-Derived Xenograft Model Market Industry Developments

Recent developments in the UK Patient-Derived Xenograft Model Market demonstrate significant progress and ongoing activity among key players. Asterand Bioscience continues to innovate in developing quality PDX models that are more representative of patient tumors. Horizon Discovery has recently expanded its services to include advanced genomic editing, enhancing the utility of PDX models in personalized medicine.

Notably, in August 2022, Crown Bioscience announced its acquisition of the assets of a notable biotech firm, positioning it for rapid growth and expanded offerings in preclinical drug development. Meanwhile, Thermo Fisher Scientific, through strategic partnerships, has integrated advanced technologies to improve PDX model reproducibility. The market shows substantial growth with estimates indicating an increase in valuation due to rising demand for personalized therapies and robust investment in cancer research.

In the past 2-3 years, there have been substantial advancements in the use of PDX models, notably in synergy with immunotherapy, signaling a pivotal shift in cancer treatment approaches in the UK. The continuous increase in funding for research initiatives underpins these trends, with companies like The Jackson Laboratory leading collaborations aimed at enhancing model applications in translational research.

UK Patient-Derived Xenograft Model Market Segmentation Insights

Patient-Derived Xenograft Model Market Tumor Type Outlook

• Lung Cancer


• Pancreatic Cancer


• Prostate Cancer


• Breast Cancer


• Other Cancer

Patient-Derived Xenograft Model Market Model Type Outlook

• Mice


• Rats

Patient-Derived Xenograft Model Market End-User Outlook

• Pharmaceutical


• Biopharmaceutical Companies


• Academic & Research Institutes


• CROs


• CDMOs

Report Scope:

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	14.12(USD Million)
MARKET SIZE 2024	16.0(USD Million)
MARKET SIZE 2035	80.0(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	15.756% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Asterand Bioscience, Horizon Discovery, Medimmune, NantCell, Ascendance Biomedical, Crown Bioscience, Tissue Solutions, Thermo Fisher Scientific, OncoOne, Charles River Laboratories, Xenograft Technologies, Genomatix, Irvine Scientific, The Jackson Laboratory, James Harper
SEGMENTS COVERED	Tumor Type, Model Type, End-User
KEY MARKET OPPORTUNITIES	Growing demand for personalized medicine, Increasing research funding and investment, Advancements in genomic technologies, Expanding applications in oncology, Collaborations between academia and industry
KEY MARKET DYNAMICS	increased cancer research funding, growing demand for personalized medicine, advances in biotechnology, rising prevalence of cancer, need for effective drug testing
COUNTRIES COVERED	UK